Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 3
2021 1
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
Davis AA, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Hensing WL, Bucheit L, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, Gradishar WJ, Behdad A, Ma CX, Bardia A, Cristofanilli M. Davis AA, et al. Among authors: bucheit l. EBioMedicine. 2022 Dec;86:104316. doi: 10.1016/j.ebiom.2022.104316. Epub 2022 Nov 1. EBioMedicine. 2022. PMID: 36332363 Free PMC article.
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
Gerratana L, Davis AA, Velimirovic M, Reduzzi C, Clifton K, Bucheit L, Hensing WL, Shah AN, Pivetta T, Dai CS, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Ma CX, Puglisi F, Bardia A, Cristofanilli M. Gerratana L, et al. Among authors: bucheit l. JCO Precis Oncol. 2023 May;7:e2200531. doi: 10.1200/PO.22.00531. JCO Precis Oncol. 2023. PMID: 37141549 Free PMC article.
Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes.
Kasi PM, Bucheit LA, Liao J, Starr J, Barata P, Klempner SJ, Gandara D, Shergill A, Madeira da Silva L, Weipert C, Zhang N, Pretz C, Hardin A, Kiedrowski LA, Odegaard JI. Kasi PM, et al. Among authors: bucheit la. JCO Precis Oncol. 2023 Sep;7:e2300118. doi: 10.1200/PO.23.00118. JCO Precis Oncol. 2023. PMID: 37769226
The gendered pay gap in genetic counseling.
Barnett C, Myers MF, Spaeth CG, Pilipenko V, Bucheit LA. Barnett C, et al. Among authors: bucheit la. J Genet Couns. 2020 Apr;29(2):182-191. doi: 10.1002/jgc4.1236. Epub 2020 Mar 3. J Genet Couns. 2020. PMID: 32128954
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.
Ma CX, Luo J, Freedman RA, Pluard TJ, Nangia JR, Lu J, Valdez-Albini F, Cobleigh M, Jones JM, Lin NU, Winer EP, Marcom PK, Thomas S, Anderson J, Haas B, Bucheit L, Bryce R, Lalani AS, Carey LA, Goetz MP, Gao F, Kimmick G, Pegram MD, Ellis MJ, Bose R. Ma CX, et al. Among authors: bucheit l. Clin Cancer Res. 2022 Apr 1;28(7):1258-1267. doi: 10.1158/1078-0432.CCR-21-3418. Clin Cancer Res. 2022. PMID: 35046057 Clinical Trial.
11 results